The combination of fructooligosaccharides and resistant starch shows prebiotic additive effects in rats

Clinical Nutrition

Volumn 29, Issue 6, 2010, Pages 832-839

  Rodríguez Cabezas, Maria Elena ^a   Camuesco, Desirée ^a   Arribas, Belén ^a   Garrido Mesa, Natividad ^a   Comalada, Mònica ^b   Bailón, Elvira ^a   Cueto Sola, Margarita ^a   Utrilla, Pilar ^a   Guerra Hernández, Eduardo ^a   Pérez Roca, Carlos ^a   Gálvez, Julio ^a   Zarzuelo, Antonio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

Author keywords

Dietary fiber; Fructooligosaccharides; Intestinal inflammation; Prebiotics; Resistant starch; TNBS rat colitis

Indexed keywords

FRUCTOSE OLIGOSACCHARIDE; INTESTINAL TREFOIL FACTOR; INTESTINAL TREFOIL FACTOR 3; MUCIN 2; PREBIOTIC AGENT; RESISTANT STARCH; STARCH; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIFIDOBACTERIUM; CECUM; COLITIS; COLON; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIETARY FIBER; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FERMENTATION TECHNIQUE; IMMUNE RESPONSE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLITIS; COLON; DIETARY FIBER; DISEASE MODELS, ANIMAL; FEMALE; FERMENTATION; LACTOBACILLUS; OLIGOSACCHARIDES; PREBIOTICS; RATS; RATS, WISTAR; STARCH; UP-REGULATION;

EID: 78649844782     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2010.05.005     Document Type: Article

References (45)

1. Roberfroid M. Prebiotics: the concept revisited. J Nutr 2007, 137(3 Suppl. 2):830S-837S.
2. Cherbut C. Inulin and oligofructose in the dietary fibre concept. Br J Nutr 2002, 87(Suppl. 2):S159-S162.
3. Nyman M. Fermentation and bulking capacity of indigestible carbohydrates: the case of inulin and oligofructose. Br J Nutr 2002, 87(Suppl. 2):S163-S168.
4. Sanderson I.R. Dietary modulation of GALT. J Nutr 2007, 137(Suppl. 11):2557S-2562S.
5. Stewart M.L., Timm D.A., Slavin J.L. Fructooligosaccharides exhibit more rapid fermentation than long-chain inulin in an in vitro fermentation system. Nutr Res 2008, 28:329-334.
6. Le Blay G., Michel C., Blottière H.M., Cherbut C. Prolonged intake of fructo-oligosaccharides induces a short-term elevation of lactic acid-producing bacteria and a persistent increase in cecal butyrate in rats. J Nutr 1999, 129:2231-2235.
7. Le Blay G., Michel C., Blottière H.M., Cherbut C. Enhancement of butyrate production in the rat caecocolonic tract by long-term ingestion of resistant potato starch. Br J Nutr 1999, 82:419-426.
8. Le Blay G.M., Michel C.D., Blottière H.M., Cherbut C.J. Raw potato starch and short-chain fructo-oligosaccharides affect the composition and metabolic activity of rat intestinal microbiota differently depending on the caecocolonic segment involved. J Appl Microbiol 2003, 94:312-320.
9. Moreau N.M., Martin L.J., Toquet C.S., Laboisse C.L., Nguyen P.G., Siliart B.S., et al. Restoration of the integrity of rat caecocolonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br J Nutr 2003, 90:75-85.
10. Rodríguez-Cabezas M.E., Gálvez J., Lorente M.D., Concha A., Camuesco D., Azzouz S., et al. Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J Nutr 2002, 132:3263-3271.
11. Camuesco D., Peran L., Comalada M., Nieto A., Di Stasi L.C., Rodriguez-Cabezas M.E., et al. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. Inflamm Bowel Dis 2005, 11:265-271.
12. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984, 87:1344-1350.
13. Camuesco D., Comalada M., Rodríguez-Cabezas M.E., Nieto A., Lorente M.D., Concha A., et al. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br J Pharmacol 2004, 143:908-918.
14. Roberfroid M.B. Inulin-type fructans: functional food ingredients. J Nutr 2007, 137(Suppl. 11):2493S-2502S.
15. Cummings J.H., Macfarlane G.T., Englyst H.N. Prebiotic digestion and fermentation. Am J Clin Nutr 2001, 73:415S-420S.
16. Hernot D.C., Boileau T.W., Bauer L.L., Middelbos I.S., Murphy M.R., Swanson K.S., et al. In vitro fermentation profiles, gas production rates, and microbiota modulation as affected by certain fructans, galactooligosaccharides, and polydextrose. J Agric Food Chem 2009, 57:1354-1361.
17. Grabitske H.A., Slavin J.L. Gastrointestinal effects of low-digestible carbohydrates. Crit Rev Food Sci Nutr 2009, 49:327-360.
18. Van de Wiele T., Boon N., Possemiers S., Jacobs H., Verstraete W. Inulin-type fructans of longer degree of polymerization exert more pronounced in vitro prebiotic effects. J Appl Microbiol 2007, 102:452-460.
19. Tytgat K.M., Bovelander F.J., Opdam F.J., Einerhand A.W., Büller H.A., Dekker J. Biosynthesis of rat MUC2 in colon and its analogy with human MUC2. Biochem J 1995, 309:221-229.
20. Mashimo H., Wu D.C., Podolsky D.K., Fishman M.C. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996, 274:262-265.
21. Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580-591.
22. Peran L., Sierra S., Comalada M., Lara-Villoslada F., Bailón E., Nieto A., et al. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr 2007, 97:96-103.
23. Peterson C.G., Sangfelt P., Wagner M., Hansson T., Lettesjö H., Carlson M. Fecal concentrations of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest 2007, 67:810-820.
24. Wagner M., Peterson C.G., Ridefelt P., Sangfelt P., Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008, 14:5584-5589.
25. Pallone F., Monteleone G. Regulatory cytokines in inflammatory bowel disease. Aliment Pharmacol Ther 1996, 10(Suppl. 2):75-79.
26. Danese S., Gasbarrini A. Chemokines in inflammatory bowel disease. J Clin Pathol 2005, 58:1025-1027.
27. Dijkstra G., Zandvoort A.J., Kobold A.C., de Jager-Krikken A., Heeringa P., van Goor H., et al. Increased expression of inducible nitric oxide synthase in circulating monocytes from patients with active inflammatory bowel disease. Scand J Gastroenterol 2002, 37:546-554.
28. Pavlick K.P., Laroux F.S., Fuseler J., Wolf R.E., Gray L., Hoffman J., et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002, 33:311-322.
29. Beck P.L., Li Y., Wong J., Chen C.W., Keenan C.M., Sharkey K.A., et al. Inducible nitric oxide synthase from bone marrow-derived cells plays a critical role in regulating colonic inflammation. Gastroenterology 2007, 132:1778-1790.
30. Abraham C., Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1090-1100.
31. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
32. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
33. Beck P.L., Wong J.F., Li Y., Swaminathan S., Xavier R.J., Devaney K.L., et al. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 2004, 126:796-808.
34. Podolsky D.K., Gerken G., Eyking A., Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 2009, 137:209-220.
35. Looijer-van Langen M.A., Dieleman L.A. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 2009, 15:454-462.
36. Allez M., Mayer L. Regulatory T cells: peace keepers in the gut. Inflamm Bowel Dis 2004, 10:666-676.
37. Kühn R., Löhler J., Rennick D., Rajewsky K., Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
38. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007, 59:1073-1083.
39. Lara-Villoslada F., de Haro O., Camuesco D., Comalada M., Velasco J., Zarzuelo A., et al. Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis. Eur J Nutr 2006, 45:418-425.
40. Lara-Villoslada F., Debras E., Nieto A., Concha A., Galvez J., Lopez-Huertas E., et al. Oligosaccharides isolated from goat milk reduce intestinal inflammation in a rat model of dextran sodium sulfate-induced colitis. Clin Nutr 2006, 25:477-488.
41. Winkler J., Butler R., Symonds E. Fructo-oligosaccharide reduces inflammation in a dextran sodium sulphate mouse model of colitis. Dig Dis Sci 2007, 52:52-58.
42. Geier M.S., Butler R.N., Giffard P.M., Howarth G.S. Prebiotic and synbiotic fructooligosaccharide administration fails to reduce the severity of experimental colitis in rats. Dis Colon Rectum 2007, 50:1061-1069.
43. Moreau N.M., Martin L.J., Toquet C.S., Laboisse C.L., Nguyen P.G., Siliart B.S., et al. Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by FOS, in DSS-induced experimental colitis. Br J Nutr 2003, 90:75-85.
44. Lindsay J.O., Whelan K., Stagg A.J., Gobin P., Al-Hassi H.O., Rayment N., et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006, 55:348-355.
45. Furrie E., Macfarlane S., Kennedy A., Cummings J.H., Walsh S.V., O'Neil D.A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005, 54:242-249.